Hangzhou TianMuShan Pharmaceutical Enterprise Co (SHSE:600671) Total Liabilities: ¥367.8 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:600671 Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd SHSE:600671
51 GF Score
Price ¥20.40
GF Value ¥15.02
Valuation Significantly Overvalued
! 10 Warning Signs
View Full Analysis

What is Hangzhou TianMuShan Pharmaceutical Enterprise Co Total Liabilities?

Hangzhou TianMuShan Pharmaceutical Enterprise Co SHSE:600671 +1.34% 51 Total Liabilities is ¥367.8 Mil as of Mar. 2026. GuruFocus rates SHSE:600671 with a GF Score™ of 51/100 and a GF Value™ of ¥15.02 (Significantly Overvalued). The stock has 10 warning signs investors should review.

Hangzhou TianMuShan Pharmaceutical Enterprise Co's Total Liabilities for the quarter that ended in Mar. 2026 was ¥367.8 Mil.

Hangzhou TianMuShan Pharmaceutical Enterprise Co's quarterly Total Liabilities increased from Sep. 2025 (¥335.43 Mil) to Dec. 2025 (¥348.04 Mil) and increased from Dec. 2025 (¥348.04 Mil) to Mar. 2026 (¥367.80 Mil).

Hangzhou TianMuShan Pharmaceutical Enterprise Co's annual Total Liabilities increased from Dec. 2023 (¥290.34 Mil) to Dec. 2024 (¥356.44 Mil) but then declined from Dec. 2024 (¥356.44 Mil) to Dec. 2025 (¥348.04 Mil).

Hangzhou TianMuShan Pharmaceutical Enterprise Co Total Liabilities Historical Data

* Premium members only.

The historical data trend for Hangzhou TianMuShan Pharmaceutical Enterprise Co's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hangzhou TianMuShan Pharmaceutical Enterprise Co Total Liabilities Chart

Hangzhou TianMuShan Pharmaceutical Enterprise Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 338.09 298.01 290.34 356.44 348.04

Hangzhou TianMuShan Pharmaceutical Enterprise Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 342.26 311.52 335.43 348.04 367.80
SHSE:600671
51GF Score
Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd SHSE:600671
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hangzhou TianMuShan Pharmaceutical Enterprise Co Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Hangzhou TianMuShan Pharmaceutical Enterprise Co's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=282.423+(8.65+56.966
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=348.0

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=442.031-93.992
=348.0

Hangzhou TianMuShan Pharmaceutical Enterprise Co's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=305.509+(7.51+54.781
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=367.8

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=464.882-97.082
=367.8

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of ¥367.8 Mil mean?
Hangzhou TianMuShan Pharmaceutical Enterprise Co (SHSE:600671) has a Total Liabilities of ¥367.8 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Hangzhou TianMuShan Pharmaceutical Enterprise Co and its competitors.
Is Hangzhou TianMuShan Pharmaceutical Enterprise Co's Total Liabilities too high?
Hangzhou TianMuShan Pharmaceutical Enterprise Co's current Total Liabilities is ¥367.8 Mil. Overall, Hangzhou TianMuShan Pharmaceutical Enterprise Co has a GF Score™ of 51/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Hangzhou TianMuShan Pharmaceutical Enterprise Co's Total Liabilities compare to LLY and JNJ?
Hangzhou TianMuShan Pharmaceutical Enterprise Co's Total Liabilities of ¥367.8 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Drug Manufacturers company?
A good Total Liabilities depends on the Drug Manufacturers industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Hangzhou TianMuShan Pharmaceutical Enterprise Co and its competitors. Hangzhou TianMuShan Pharmaceutical Enterprise Co's current Total Liabilities is ¥367.8 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hangzhou TianMuShan Pharmaceutical Enterprise Co stock overvalued right now?
Based on GuruFocus' analysis, Hangzhou TianMuShan Pharmaceutical Enterprise Co (SHSE:600671) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥15.02, compared to a current price of ¥20.40 — trading 35.8% above its estimated fair value. The current Total Liabilities is ¥367.8 Mil. Hangzhou TianMuShan Pharmaceutical Enterprise Co's overall GF Score™ is 51/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Hangzhou TianMuShan Pharmaceutical Enterprise Co (SHSE:600671), the current Total Liabilities is ¥367.8 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Hangzhou TianMuShan Pharmaceutical Enterprise Co (SHSE:600671) Overvalued in 2026?

Based on GuruFocus' analysis, Hangzhou TianMuShan Pharmaceutical Enterprise Co stock appears to be overvalued. The current stock price of ¥20.40 is trading 35.8% above its estimated GF Value™ of ¥15.02. GuruFocus considers Hangzhou TianMuShan Pharmaceutical Enterprise Co to be Significantly Overvalued.

Key valuation signals for SHSE:600671:

  • Total Liabilities: ¥367.8 Mil
  • GF Value™: ¥15.02 vs. price of ¥20.40 (35.8% above fair value)
  • GF Score™: 51/100 with 10 warning signs

No single metric tells the full story. See the SHSE:600671 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Hangzhou TianMuShan Pharmaceutical Enterprise Co Business Description

Address No.18 Shangyang Road, Jinnan Street, Lin'an District, Zhejiang Province, Hangzhou, CHN, 311200
Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd is engaged in producing proprietary Chinese medicines, biopharmaceuticals, healthy foods, medical equipment, and other medicines in China.
51GF Score

Get the complete analysis for SHSE:600671

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥20.40
Price
¥15.02
GF Value